Research library / Resveratrol and sirtuins
CC Small or few human trials. Promising, not proven. How we grade →RCT · 24 obese men
High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition
M Poulsen, P Vestergaard, B Clasen, Y Radko, L Christensen, H Stødkilde-Jørgensen et al. Diabetes. 2013.
- In plain language
- 1,500 mg of resveratrol a day for 4 weeks did not change insulin sensitivity on the clamp test (the primary outcome), glucose turnover, blood pressure, energy expenditure, liver or visceral fat, or inflammatory markers.
- Limits
- Small and short. Investigator-initiated, funded by Danish public agencies and foundations; no relevant conflicts reported.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Resveratrol: mice, lifespan and people
- Source
- doi.org/10.2337/db12-0975 · PubMed 23193181 · Free full text
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.